Pregledni rad

Treatment of nonalcoholic fatty liver disease

Ivana Mikolašević ; Zavod za gastroenterologiju, KBC Rijeka, Rijeka
Sandra Milić ; Zavod za gastroenterologiju, KBC Rijeka, Rijeka
Lidija Orlić ; Zavod za nefrologiju, dijalizu i transplantaciju bubrega, KBC Rijeka, Rijeka
Marija Stanić ; Zavod za hematologiju i kliničku imunologiju, KBC Rijeka, Rijeka
Davor Štimac ; Zavod za gastroenterologiju, KBC Rijeka, Rijeka
Vojko Mavrinac ; Zavod za gastroenterologiju, KBC Rijeka, Rijeka
Vera Vlahović-Palčevski ; Zavod za kliničku farmakologiju, KBC Rijeka, Rijeka

Sažetak

Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease worldwide. NAFLD is a liver manifestation of metabolic syndrome, along with hypertension, diabetes, dyslipidemia and insulin resistance. Nonalcoholic steatohepatitis (NASH) is a progressive form of NAFLD, which often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma. There is no optimal treatment for NAFLD and most treatment options are based on lifestyle changes, diet and physical activity. Medications that are reducing insulin resistance, vitamin E and D and renin-angiotensin-aldosterone system blockers have shown promising results, but their long-term effectiveness and safety remains to be established.

Ključne riječi

metabolic syndrome X; non-alcoholic fatty liver disease; therapy

Hrčak ID:

158496

URI

https://hrcak.srce.hr/158496

Datum izdavanja:

1.6.2016.

Podaci na drugim jezicima: hrvatski

Posjeta: 3.983 *